Document is current

Article History

Received: 16 May 2025

Accepted: 17 November 2025

First Online: 4 February 2026

Declarations

:

: Yasmin H. Karimi reports consultancy for and honoraria from AbbVie and ADC Therapeutics; research funding from AbbVie, AstraZeneca, Lilly/Loxo, Merck, Roche/Genentech, and Xencor; and receiving travel expenses support from Roche/Genentech. Chan Y. Cheah reports consultancy and advisory role for, or honoraria from AbbVie, AstraZeneca, BeiGene, BMS, CRISPR Therapeutics, Dizal, Genmab, Gilead, Janssen, Lilly, Menarini, Roche, Regeneron, and Sobi; speakers bureau participation for AbbVie, AstraZeneca, BeiGene, Genmab, Janssen, MSD, and Roche; research funding from AbbVie, BMS, Lilly, MSD, and Roche; and receiving travel expenses support from BeiGene and Lilly. Michael Roost Clausen reports advisory role for AbbVie, AstraZeneca, Genmab, Gilead, Incyte, Janssen, and Roche; and receiving travel expenses support from AbbVie, AstraZeneca, Genmab, Janssen, Pfizer, and Roche. David Cunningham reports research funding from 4SC, Bayer, Celgene, Clovis, Eli Lilly, and Roche. Umar Farooq reports membership on the Kite Pharma advisory board. Tatyana Feldman reports consultancy for AbbVie, AstraZeneca, Epizyme, Genmab, Gilead/Kite, Karyopharm, Seagen, and Takeda; and speakers bureau participation for Seagen. Herve Ghesquieres reports consultancy for BMS, Roche, and Takeda; and honoraria from AbbVie, BMS, Gilead, Roche, and Takeda. Wojciech Jurczak reports consultancy for and research funding from AbbVie, AstraZeneca, BeiGene, Janssen Cilag, Lilly, Regeneron, Roche, and Takeda; and research funding from Merck, and MSD. Kim M. Linton reports research funding from AbbVie, BeiGene, BMS, Celgene, Genmab, Kite/Gilead, and Roche; consultancy for AbbVie, BeiGene, BMS, Celgene, Genmab, and Kite/Gilead; research support by the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC) (NIHR203308); speakers bureau participation for AbbVie, BMS, and Celgene; receiving travel expenses support from Celgene, BMS; and membership on the Epcoritamab Global Council for Genmab. Catherine Thieblemont reports honoraria, consulting, or advisory role, and receiving travel/accommodation expenses support from AbbVie, BMS, Roche, and Novartis. Tycel Phillips reports research funding (scholar in clinical research of The Leukemia & Lymphoma Society) from AbbVie, Bayer, Pharmacyclics/Janssen, and Genentech, a member of the Roche Group; membership on an entity’s board of directors or advisory committees for AbbVie, Genentech, a member of the Roche Group, Genmab, and Merck; honoraria from Lymphoma & Myeloma Connect, and Seattle Genetics; research funding from AbbVie and Genentech, a member of the Roche Group; consultancy for AbbVie, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, BMS, Caribou, Epizyme, Genentech, a member of the Roche Group, Genmab, Gilead, Incyte, Lilly, and Pharmacy. Won Seog Kim reports research funding from BeiGene, Boryung, Dong-A, F. Hoffmann-La Roche Ltd, Kyowa Kirin, and Sanofi; and speakers bureau participation for Kumode, Janssen Pharmaceutical and Ono Pharmaceutical. Pegah Jafarinasabian reports being currently employed by and owning stocks in AbbVie. Barbara D’Angelo Månsson reports being currently employed by and owning stocks in Genmab. David Soong reports being currently employed by and owning stocks in Genmab. Andrew J. Steele reports being currently employed by Genmab and owning stocks in AbbVie, Genmab, and Johnson & Johnson. Zhu Li reports being currently employed by Genmab. Christian W. Eskelund reports being currently employed by Genmab. Martin Hutchings reports consultancy, advisory role for, or honoraria from AbbVie, AstraZeneca, Genmab, Johnson & Johnson, Merck, Roche, Takeda; and research support (paid to institution) from AbbVie, Arvinas, AstraZeneca, BMS, Celgene, Genentech, Genmab, Incyte, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, and Takeda. Julie M. Vose reports research study support from AbbVie, Genmab, Loxo, and Seagen; and consultancy for AbbVie, Genentech, and Genmab.